
Clinical Briefs
SGLT2 Inhibitors Linked to Better HFpEF Outcomes in Type 2 Diabetes
A nationwide cohort associated SGLT2 inhibitors with lower heart-failure hospitalization and all-cause mortality risks than DPP-4 inhibitors or sulfonylureas in HFpEF and type 2 diabetes.
Dr. Abu Bakar · September 27, 2026 · 6 min
